Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nutriband Inc. (NTRB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nutriband uses current reports on Form 8-K to furnish material information, including press releases that describe developments in its AVERSA abuse-deterrent transdermal technology platform and its lead product candidate, an abuse-deterrent fentanyl transdermal system.
Through these filings, investors can review how Nutriband reports regulatory interactions with the U.S. Food and Drug Administration, such as meetings to discuss Chemistry, Manufacturing, and Controls plans, the 505(b)(2) NDA pathway for AVERSA Fentanyl, and planned in vitro studies to characterize abuse-deterrent properties. Filings may also reference intellectual property actions, including patent allowances and provisional patent applications intended to strengthen and extend protection for the AVERSA technology.
Nutriband’s SEC documents can further detail corporate and capital structure events, such as preferred stock dividends linked to potential future FDA approval of AVERSA Fentanyl, warrant-related information, and transactions like the sale of a majority interest in subsidiary Pocono Pharmaceutical to EarthVision Bio. These filings provide formal context around how the company allocates resources toward the development of its transdermal pharmaceutical portfolio.
On Stock Titan, Nutriband filings are updated as they are made available through EDGAR, and AI-powered tools summarize key points from lengthy documents. Users can quickly identify the main topics in each filing, such as regulatory strategy, product development milestones, or financing-related disclosures, and then drill down into the full text for detailed review. This structure helps investors and researchers understand how Nutriband presents its business, technology, and risk factors in its official SEC communications.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband Inc. files a prospectus supplement updating warrant information and incorporating recent Form 10-Q disclosures. The supplement states the Company issued 1,232,000 warrants in the October 5, 2021 offering and that 910,904 warrants were outstanding as of
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported modest revenue growth but significantly higher losses for the quarter and nine months ended October 31, 2025. Revenue for the quarter fell to
Despite a nine‑month gross profit of
Nutriband ended the period with cash of
NutriBand Inc. (NTRB) CEO and director Gareth Sheridan, who is also a 10% owner, reported his annual holdings for the fiscal year ended 01/31/2025. He beneficially owned 1,761,667 shares of NutriBand common stock in direct ownership at year-end.
Sheridan also reported stock options as derivative securities. On 03/20/2024, he received stock options for 97,500 shares with a $2.61 exercise price, expiring on 03/20/2027. On 01/29/2025, he received additional stock options for 29,333 shares with a $8.07 exercise price, expiring on 01/29/2028. Following these transactions, he held 251,000 stock options in total, all reported as directly owned.
NutriBand (NTRB) CFO Gerald Goodman filed a Form 5 for the fiscal year ended 01/31/2025, reporting year-end holdings and prior transactions under Section 16. The filing shows 66,085 shares of common stock beneficially owned at fiscal year-end, held directly.
Reported transactions include: acquisition of 60,085 common shares at $1.93 on 10/27/2023; a warrant at $1.93 tied to 60,085 underlying shares with an expiration date of 10/27/2026; a stock option grant for 75,000 shares at $1.93 on 03/19/2024 expiring 03/19/2027; and a stock option grant for 17,667 shares at $7.34 on 01/23/2025 expiring 01/23/2028. Ownership is indicated as direct for the securities listed.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.